Poor T-cell receptor β repertoire diversity early posttransplant for severe combined immunodeficiency predicts failure of immune reconstitution.

"Disclosure of potential conflict of interest: M. J. Cowan, C. C. Dvorak, L. D. Notarangelo, and J. M. Puck declare receipt of royalty payments from UpToDate. M. J. Cowan is on Scientific Advisory Board and owns stock in Homology Medicine, Inc. The spouse of J. M. Puck is employed by and holds stock in Invitae, Inc. The rest of the authors declare that they have no relevant conflicts of interest."

"The Primary Immune Deficiency Treatment Consortium is funded by the National Institute of Allergy and Infectious Diseases (NIAID; grant no. U54-AI082973) and the Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health (NIH), Bethesda, Md. Additional funding has come from the Division of Intramural Research, NIAID, NIH (grant no. 1 ZIA AI001222-02 to L.D.N.) and the California Institute of Regenerative Medicine (grant no. CLIN2-10830 to M.J.C. and grant no. CLIN2-09504 to Dr Gottschalk, supporting gene therapy trials for DCLRE1C and IL2RG SCID). J.M.P received further support from the Lisa and Douglas Goldman Fund."